HUTCHMED Announces Major Licensing Agreement with GSK for Experimental Cancer Therapy
HUTCHMED shares surged by over 16% following the announcement of a licensing deal with GlaxoSmithKline (GSK) worth up to $1.295 billion for its experimental cancer therapy HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted treatment for solid tumors. GSK will pay an upfront fee of $110 million and may make additional payments based on development milestones. The deal has been positively received by analysts, with Daiwa Securities upgrading HUTCHMED from 'hold' to 'buy,' while Panmure Liberum and Cavendish reaffirmed their 'buy' ratings. The partnership is seen as a validation of HUTCHMED’s oncology pipeline and commercial potential. HUTCHMED also highlighted the success of its late-stage trial combining Orpathys with AstraZeneca's Tagrisso for lung cancer, further reinforcing investor confidence in its drug development capabilities.
-limited-logo.png?v=20221128110814){kind=logo}
Topics: licensing agreement oncology pipeline pharma partnership